Rite Aid offers bathing facilities to victims of California wildfires
CAMP HILL, Pa. To further assist the evacuees of the San Diego County wildfires, Rite Aid has provided bathing facilities and bathing linens to those displaced by the emergency at the New Song Community Church shelter in Oceanside, Calif. Rite Aid also reported that their local stores have provided food, beverages and personal items to those at the shelter.
On Tuesday, Rite Aid shipped more than $75,000 of supplies, including eye drops, lip balm, sunscreen and hand sanitizer, to the American Red Cross chapter in San Diego County to be distributed at various shelters. The Rite Aid Foundation has also donated $100,000 to the American Red Cross to help with relief efforts in San Diego County.
“Rite Aid responded immediately and generously to support families who were forced out of their homes by fire,” said Rep. Darrell Issa, R-Calif., who alerted Rite Aid officials about the need for access to the facilities after visiting the evacuation shelter on Wednesday. “We greatly appreciate Rite Aid’s contribution to the community-wide effort to care for our neighbors in this time of crisis.”
Like several other drug stores in the area, Rite Aid is offering customers the opportunity to fill or pick up their prescriptions at any open Rite Aid, even if their neighborhood store has been evacuated. This includes prescriptions that have been filled at a store that might be closed but not yet picked up.
GSK ready to cut jobs following quarterly losses
PHILADELPHIA GlaxoSmithKline is ready to let some of its workers go to make up for its recent report of lost earnings.
The company reported that total pharmaceutical turnover for the third quarter fell by 2% to $9.4 billion. In the United States, turnover fell 7% to $4.5 billion, impacted by continued generic competition and largely because of a 38 percent drop in sales of its diabetes drug Avandia.
The plan is a three-year $1.4 billion move that includes job cuts, most likely starting at its Avandia sales force. According to the London Times, the company is awaiting what the Food and Drug Administration will report about their findings on Avandia and if it should receive a “black box” warning for heart attack risks.
FDA approves Marillion NDA for novel cancer treatment
MALVERN, Pa. Marillion Pharmaceuticals has received approval from the Food and Drug Administration for it investigational new drug application for its lead product candidate MN-201, a vitamin D5 analog for the treatment of cancer.
The drug will now proceed to Phase 1 human clinical trial for patients with advanced tumors in various cancers.
In preclinical studies, MN-201 performed well against cancer cells. In animal models, MN-201 also resulted in anti-tumor activity including tumor regression in xenograft models of major solid tumor types. In contrast to treatment with other vitamin D(3) analogs and the naturally occurring vitamin D hormone, calcitriol, favorable anticancer effects with MN-201 were observed in the absence of significantly raised calcium levels.